In consideration of the reported significant roles of both Src and p300 in hormone receptor signaling [36, 43], current studies raise the possibility that the novel Src/p300-dependent signaling occurs in hormone receptor positive tumors, such as breast and prostate cancers. Here, EP300 is linked to Familial prostate cancer.